Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors

Table 1

Clinical and laboratory changes in patients with RA and mono- or oligoarthritis treated with CZP.

Case	Age/sex	Stage	DD (year)	DMARD	Prior biologics (duration)	NSJ/NTJ; prior→before→after	DAS28-CRP; prior→before→after	Imaged joint	PD (grade)
									Before	After	Duration
1	27 F	I	4	MTX	GLM (12 m)	4/3→1/1→0/0	3.87→2.21→1.45	Wrist	2	0	2 m
2	41 F	III	2	BUC	GLM (10 m)	1/3→1/1→0/0	2.34→2.02→1.11	1st IP	2	0	3 m
3	39 F	III	13	MTX	IFX (15 m), ETN (30 m)	2/4→2/2→0/1	3.82→3.46→1.76	Wrist	2	0	1.5 m
4	62 F	II	4	MTX	ETN (32 m)	5/6→3/1→1/0	4.24→3.05→1.88	Elbow	2	0	1 m
Mean	42.3				24.8 m	3/4→1.75/1.250.25/0.25	3.56→2.69→1.55		2	0	1.9 m
(SD)	(14.5)				(16.8 m)		(0.84) (0.68) (0.34)				(0.9 m)

DD: disease duration, NSJ/NTJ: the number of swollen and tender joints, m: month(s), F: female, stage: Steinbrocker classification, MTX: methotrexate, BUC: bucillamine, GLM: golimumab, IFX: infliximab, ETN: etanercept. Prior: DAS28 scores prior to treatment with the 1st TNF-inhibitor.